Encysive Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Houston TX United States (1989)
Status: Acquired by Pfizer (2008)

Organization Overview

First Clinical Trial
2002
NCT00034307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Encysive Pharmaceuticals | Revotar Biopharmaceuticals AG | Texas Biotechnology Corporation

Active Ingredients

Marketed Drugs (1)

argatroban (NDA)

Drugs in Phase 4 Trials (1)

argatroban (2 trials)

Drugs in Phase 3 Trials (1)

sitaxentan (4 trials)

Drugs in Phase 2 Trials (2)

nifedipine (procardia) (1 trial)

tbc-1269 (3 trials)

Drugs in Phase 1 Trials (2)

bosentan (tracleer) (1 trial)

endothelin-3 (1 trial)

Indications

Approved Indications


 

Thrombocytopenia

Thrombosis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Familial Primary Pulmonary Hypertension (Phase 3)

Hypertension (Phase 3)

Hypertension, Pulmonary (Phase 3)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Proteinuria (Phase 2)

Psoriasis (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 2)

Thrombocytopenia (Phase 4)

Thrombosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 6